

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

1. (currently amended) Reagent, characterized in that, in at least two spatially separated positions on a cell-bound or soluble target molecule, the reagent enters into interactions with said cell-bound or soluble target molecule;

wherein the reagent is selected from the group consisting of antibodies, antibody fragments, chimerized antibodies, humanised antibodies, single chain (sc)Fv fragments, scT-cell receptor (TCR) fragments, and hybrid scFv/scTCR fragments,;

wherein said cell-bound or soluble target molecule is CD30; and

wherein said at least two spatially separated positions each comprise an epitope having a core sequence CEPDY (SEQ ID NO:13), and the reagent enters into interactions with each of said at least two spatially separated positions on said cell-bound or soluble target molecule via binding to said epitope with a core sequence CEPDY (SEQ ID NO:13).

Claims 2-5. (canceled)

6. (previously presented) Reagent according to one of the claim 1, characterized in that the reagent is a chimerized antibody or a fragment of the same.

7. (previously presented) Reagent according to one of the claim 1, characterized in that the reagent is available from a culture medium of the cell DSZ1 stored at the German Microorganisms Collection (DSM) under the number DSM ACC2548.

8. (previously presented) Reagent according to one of the claim 1, characterized in that it also contains a toxin and/or a marking.

9. (previously presented) Reagent according to Claim 8, characterized in that it is linked peptidically or via linker molecules with toxic proteins or with enzymes or proenzymes.

10. (withdrawn, previously presented) Reagent according to Claim 9, characterized in that it is linked with toxins in the form of ribosome-inactivating proteins.

11. (previously presented) Reagent according to Claim 9, characterized in that it is linked with enzymes from the group of the phosphodiesterases.

12. (withdrawn, previously presented) Reagent according to Claim 9, characterized in that it is linked directly or via a linker molecule covalently or conjugated with radioactive isotopes.

13. (withdrawn, previously presented) Reagent according to Claim 12, characterized in that the radioactive isotopes are selected from the group consisting of indium, iodine, yttrium, technetium, rhenium, copper and lutetium.

14. (withdrawn, previously presented) Reagent according to claim 8, characterized in that it is linked directly or via linker molecules covalently or conjugated with photactivatable compounds.

15. (currently amended) Isolated cell Cell which produces a reagent according to claim 1.

16. (currently amended) Isolated cell Cell according to Claim 15, characterized in that it contains a recombinant DNA which codes for the reagent or a part thereof.

17. (currently amended) Isolated cell Cell according to claim 15, characterized in that it shows essential features of the cell as stored at the DSM under no. DSM

ACC2548, especially the ability to give off the antibody in a considerably higher concentration into the medium than comparable cells.

18. (currently amended) Isolated cell Cell according to claim 15, characterized in that it was stored at the DSM under the no. DSM ACC2548.

19. (withdrawn, previously amended) Method for the diagnosis especially of tumours and inflammatory diseases, characterized in that a sample from the test person is contacted with a reagent according to claim 1 and the extent of the reaction of the reagent with the sample is determined.

20. (withdrawn, previously presented) Method for the diagnosis of diseases, characterized in that the diagnosis is carried out in vivo and that it covers, for example, a scintigraphy.

21. (withdrawn) A method of treating a patient having tumours, inflammatory, inflammatory-allergic and/or autoimmune diseases, comprising dispensing a reagent according to claim 1.

22. (withdrawn, previously presented) The method according to Claim 21, characterized in that the tumour is a lymphoma or embryonal carcinoma.

23. (withdrawn, previously presented) The method according to Claim 22, characterized in that the lymphoma is a CD30-positive lymphoma.

24. (withdrawn, previously presented) The method according to Claim 23, characterized in that the CD30-positive lymphoma is a Hodgkin's lymphoma, an anaplastic large-cell lymphoma or an acute or lymphomatous form of adult T-cell leukaemia.

25. (withdrawn, previously presented) The method according to claim 21, characterized in that 10 to 1000 mg/m<sup>2</sup> body surface of reagent is dispensed.

26. (withdrawn, previously presented) The method according to Claim 25, characterized in that 20 to 400 mg/m<sup>2</sup> body surface of reagent is dispensed.

27. (withdrawn, previously presented) The method according to claim 21, characterized in that the reagent is dispensed i.v.

28. (withdrawn, previously presented) A method of making a composition for the suppression or avoidance of a rejection reaction and/or a graft-versus-host reaction in the transplantation of organs, bone marrow or stem cells comprising incorporating a reagent according to claim 1 into a composition.

29. (previously presented) Pharmaceutical composition containing a reagent according to claim 1.

30. (previously presented) Kit for the diagnosis in particular of tumours, especially CD30-positive neoplasies, and inflammatory diseases, containing a reagent according to claim 1 together with instructions for use for the reagent.